TURING BIOSYSTEMS

Startup

Turing Biosystems was founded in 2022 by Adam, a synthetic biologist, and Remy, a software engineer and semiconductor design specialist. We are a biotech startup with a passion for facilitating better therapy design and improving patient outcomes by catalysing the convergence between biology and computing. Our software platform, inspired by semiconductor design technology, integrates and creates associative networks between any and all types of clinical and biological data, offering a solution to the major problems currently faced by healthcare and pharma: low response rates, high adverse events, and the high cost of treatment. In an early partnership on liver cancer, we discovered new biomarkers and new potential therapy combinations with immune mechanistic insights to trigger response to immune checkpoint inhibitors for hepatocellular carcinoma. We are currently working with other clinical partners on immunotherapy response optimization in melanoma, lung cancer, and head and neck cancers. In addition, we are running a project with a gene therapy company to reduce immune adverse events to their product(s), as well as a project on tumour spatial response to immunotherapy with a large pharma.

website